Publications

  1. Graf I, Herndlhofer S, Kundi M, Greiner G, Sperr M, Hadzijusufovic E, Valent P, Sperr WR. Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population. Eur J Haematol. 2023 Jan;110(1):67-76. doi: 10.1111/ejh.13875. Epub 2022 Oct 17. PMID: 36193973.
  2. Vekariya U, Toma MM, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszywalow-Bartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, Jelinek J, Sliwinski T, Ghosh J, Matlawska-Wasowska K, Chandramouly G, Nejati R, Wasik MA, Sykes S, Piwocka K, Hadzijusufovic E, Valent P, Pomerantz RT, Morton G, Childers W, Zhao H, Paietta E, Levine RL, Tallman MS, Fernandez H, Litzow MR, Gupta G, Masson JY, Skorski T. DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage. Blood. 2022 Dec 29:blood.2022018428. doi: 10.1182/blood.2022018428. Epub ahead of print. PMID: 36580665.
  3. Porwit A, Béné MC, Duetz C, Matarraz S, Oelschlaegel U, Westers TM, Wagner-Ballon O, Kordasti S, Valent P, Preijers F, Alhan C, Bellos F, Bettelheim P, Burbury K, Chapuis N, Cremers E, Della Porta MG, Dunlop A, Eidenschink-Brodersen L, Font P, Fontenay M, Hobo W, Ireland R, Johansson U, Loken MR, Ogata K, Orfao A, Psarra K, Saft L, Subira D, Te Marvelde J, Wells DA, van der Velden VHJ, Kern W, van de Loosdrecht AA. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group. Cytometry B Clin Cytom. 2022 Dec 20. doi: 10.1002/cyto.b.22108. Epub ahead of print. PMID: 36537621.
  4. Lübke J, Schwaab J, Christen D, Elberink HO, Span B, Niedoszytko M, Gorska A, Lange M, Gleixner KV, Hadzijusufovic E, Solomianyi O, Angelova-Fischer I, Zanotti R, Bonifacio M, Bonadonna P, Shoumariyeh K, von Bubnoff N, Müller S, Perkins C, Elena C, Malcovati L, Hagglund H, Mattsson M, Parente R, Varkonyi J, Fortina AB, Caroppo F, Zink A, Brockow K, Breynaert C, Bullens D, Yavuz AS, Doubek M, Sabato V, Schug T, Niederwieser D, Hartmann K, Triggiani M, Gotlib J, Hermine O, Arock M, Kluin-Nelemans HC, Panse J, Sperr WR, Valent P, Reiter A, Jawhar M. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis. J Allergy Clin Immunol Pract. 2022 Nov 17:S2213-2198(22)01197-7. doi: 10.1016/j.jaip.2022.10.051. Epub ahead of print. PMID: 36403897.
  5. Heinemann T, Kornauth C, Severin Y, Vladimer GI, Pemovska T, Hadzijusufovic E, Agis H, Krauth MT, Sperr WR, Valent P, Jäger U, Simonitsch-Klupp I, Superti-Furga G, Staber PB, Snijder B. Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine. Blood Cancer Discov. 2022 Nov 2;3(6):502-515. doi: 10.1158/2643-3230.BCD-21-0219. PMID: 36125297.
  6. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Metcalfe DD, Galli SJ. New Insights Into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy. Annu Rev Pathol. 2022 Oct 21. doi: 10.1146/annurev-pathmechdis-031521-042618. Epub ahead of print. PMID: 36270293.
  7. Zeilinger EL, Oppenauer C, Knefel M, Kantor V, Schneckenreiter C, Lubowitzki S, Krammer K, Popinger C, Kitta A, Kum L, Adamidis F, Unseld M, Masel EK, Füreder T, Zöchbauer-Müller S, Bartsch R, Raderer M, Prager G, Krauth MT, Sperr WR, Porpaczy E, Staber PB, Valent P, Gaiger A. Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study. Epidemiol Psychiatr Sci. 2022 Oct 17;31:e74. doi: 10.1017/S2045796022000592. PMID: 36245424; PMCID: PMC9583630.
  8. Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. Proposed Refined Diagnostic Criteria and Classification of Eosinophil Disorders and Related Syndromes. Allergy. 2022 Oct 7. doi: 10.1111/all.15544. Epub ahead of print. PMID: 36207764.
  9. Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol. 2022 Oct;40(4):491-504. doi: 10.1002/hon.2987. Epub 2022 Apr 15. PMID: 35368098.
  10. Grunt TW, Valent P. Cancer – A devastating disease, but also an eye-opener and window into the deep mysteries of life and its origins. Prog Biophys Mol Biol. 2022 Nov;175:131-139. doi: 10.1016/j.pbiomolbio.2022.09.009. Epub 2022 Oct 2. PMID: 36198374.
  11. Moyo TK, Mendler JH, Itzykson R, Kishtagari A, Solary E, Seegmiller AC, Gerds AT, Ayers GD, Dezern AE, Nazha A, Valent P, van de Loosdrecht AA, Onida F, Pleyer L, Cirici BX, Tibes R, Geissler K, Komrokji RS, Zhang J, Germing U, Steensma DP, Wiseman DH, Pfeilstöecker M, Elena C, Cross NCP, Kiladjian JJ, Luebbert M, Mesa RA, Montalban-Bravo G, Sanz GF, Platzbecker U, Patnaik MM, Padron E, Santini V, Fenaux P, Savona MR; MDS/MPN International Working Group. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. BMC Cancer. 2022 Sep 24;22(1):1013. doi: 10.1186/s12885-022-10073-w. PMID: 36153475.
  12. Kennedy VE, Perkins C, Reiter A, Jawhar M, Lübke J, Kluin-Nelemans HC, Shomali W, Langford C, Abuel J, Hermine O, Niedoszytko M, Gorska A, Mital A, Bonadonna P, Zanotti R, Tanasi I, Mattsson M, Hagglund HG, Triggiani M, Yavuz AS, Panse JP, Christen D, Heizmann M, Shoumariyeh K, Müller S, Elena C, Malcovati L, Fiorelli N, Wortmann F, Vucinic V, Brockow K, Fokoloros C, Papageorgiou SG, Breynaert C, Bullens D, Doubek M, Ilerhaus A, Angelova-Fischer I, Solomianyi O, Varkonyi J, Sabato V, Rüfer A, Schug T, Hermans MAW, Belloni Fortina A, Caroppo F, Bumbea H, Gulen T, Hartmann K, Oude Elberink H, Schwaab J, Arock M, Valent P, Sperr W, Gotlib J. Mast Cell Leukemia: Clinical and Molecular Features and Survival Outcomes of Patients in the ECNM Registry. Blood Adv. 2022 Sep 12:bloodadvances.2022008292. doi: 10.1182/bloodadvances.2022008292. Epub ahead of print. PMID: 36094848.
  13. Valent P. Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic Algorithm. J Allergy Clin Immunol Pract. 2022 Sep;10(9):2375-2377. doi: 10.1016/j.jaip.2022.06.027. PMID: 36087944.
  14. Gaiger A, Lubowitzki S, Krammer K, Zeilinger EL, Acel A, Cenic O, Schrott A, Unseld M, Rassoulian AP, Skrabs C, Valent P, Gisslinger H, Marosi C, Preusser M, Prager G, Kornek G, Pirker R, Steger GG, Bartsch R, Raderer M, Simonitsch-Klupp I, Thalhammer R, Zielinski C, Jäger U. The cancer survival index-A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. Cancer Med. 2022 Sep;11(18):3387-3396. doi: 10.1002/cam4.4697. Epub 2022 Mar 22. PMID: 35315594; PMCID: PMC9487871.
  15. Peter B, Eisenwort G, Sadovnik I, Bauer K, Willmann M, Rülicke T, Berger D, Stefanzl G, Greiner G, Hoermann G, Keller A, Wolf D, Čulen M, Winter GE, Hoffmann T, Schiefer AI, Sperr WR, Zuber J, Mayer J, Valent P. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia. Am J Hematol. 2022 Sep;97(9):1215-1225. doi: 10.1002/ajh.26650. Epub 2022 Jul 18. PMID: 35794848; PMCID: PMC9546315.
  16. Smiljkovic D, Herrmann H, Sadovnik I, Gamperl S, Berger D, Stefanzl G, Eisenwort G, Hoermann G, Kopanja S, Dorofeeva Y, Focke-Tejkl M, Jaksch P, Hoetzenecker K, Szepfalusi Z, Valenta R, Arock M, Valent P. Expression and Regulation of Siglec-6 (CD327) on Human Mast Cells and Basophils. J Allergy Clin Immunol. 2022 Aug 8:S0091-6749(22)01044-2. doi: 10.1016/j.jaci.2022.07.018. Epub ahead of print. PMID: 35953001.
  17. Hutter K, Rülicke T, Szabo TG, Andersen L, Villunger A, Herzog S. The miR-15a/16-1 and miR-15b/16-2 clusters regulate early B cell development by limiting IL-7 receptor expression. Front Immunol. 2022 Aug 25;13:967914. doi: 10.3389/fimmu.2022.967914. PMID: 36110849; PMCID: PMC9469637.
  18. Hoermann G, Sotlar K, Jawhar M, Kristensen T, Bachelot G, Nedoszytko B, Carter MC, Horny HP, Bonadonna P, Sperr WR, Hartmann K, Brockow K, Lyons JJ, Kluin-Nelemans HC, Hermine O, Akin C, Broesby-Olsen S, Triggiani M, Butterfield JH, Schwaab J, Reiter A, Gotlib J, Metcalfe DD, George TI, Orfao A, Valent P, Arock M. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1953-1963. doi: 10.1016/j.jaip.2022.03.001. Epub 2022 Mar 11. PMID: 35283331.
  19. Valent P, Hartmann K, Schwaab J, Alvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Carter MC, Hoermann G, Sperr WR, Butterfield JH, Ustun C, Zanotti R, Radia DH, Castells M, Triggiani M, Schwartz LB, Orfao A, George TI, Sotlar K, Gotlib J, Reiter A, Horny HP, Arock M, Akin C, Metcalfe DD. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1999-2012.e6. doi: 10.1016/j.jaip.2022.03.007. Epub 2022 Mar 25. PMID: 35342031.
  20. Valent P, Hartmann K, Bonadonna P, Gülen T, Brockow K, Alvarez-Twose I, Hermine O, Niedoszytko M, Carter MC, Hoermann G, Butterfield JH, Lyons JJ, Sperr WR, Greiner G, Sotlar K, Kluin-Nelemans HC, Schwaab J, Lange M, George TI, Siebenhaar F, Broesby-Olsen S, Jawhar M, Nedoszytko B, Castells M, Orfao A, Gotlib J, Reiter A, Horny HP, Triggiani M, Arock M, Metcalfe DD, Akin C. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1941-1950. doi: 10.1016/j.jaip.2022.05.007. Epub 2022 May 25. PMID: 35623575.
  21. Gotlib J, Schwaab J, Shomali W, George TI, Radia DH, Castells M, Carter MC, Hartmann K, Álvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Hoermann G, Sperr WR, Elberink HO, Siebenhaar F, Butterfield JH, Ustun C, Zanotti R, Triggiani M, Schwartz LB, Lyons JJ, Orfao A, Sotlar K, Horny HP, Arock M, Metcalfe DD, Akin C, Lübke J, Valent P, Reiter A. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2025-2038.e1. doi: 10.1016/j.jaip.2022.05.034. Epub 2022 Jun 18. PMID: 35724948.
  22. Sotlar K, George TI, Kluin P, Reiter A, Schwaab J, Panse J, Brockow K, Hartmann K, Sperr WR, Kristensen T, Nedoszytko B, Carter M, Bonadonna P, Lyons JJ, Kluin-Nelemans HC, Hermine O, Akin C, Broesby-Olsen S, Hoermann G, Triggiani M, Butterfield JH, Jawhar M, Gotlib J, Metcalfe DD, Orfao A, Arock M, Valent P, Horny HP. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1986-1998.e2. doi: 10.1016/j.jaip.2022.05.036. Epub 2022 Jun 18. PMID: 35724949.
  23. Pyatilova P, Akin C, Alvarez-Twose I, Arock M, Bonadonna P, Brockow K, Butterfield JH, Broesby-Olsen S, Carter MC, Castells M, George TI, Gotlib J, Greiner G, Gülen T, Hartmann K, Hermine O, Horny HP, Jawhar M, Lange M, Lyons JJ, Maurer M, Metcalfe DD, Nedoszytko B, Niedoszytko M, Orfao A, Reiter A, Schwaab J, Sotlar K, Sperr WR, Triggiani M, Valent P, Siebenhaar F. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2015-2024. doi: 10.1016/j.jaip.2022.05.037. Epub 2022 Jun 18. PMID: 35724950.
  24. Jennings SV, Finnerty CC, Hobart JS, Martín-Martínez M, Sinclair KA, Slee VM, Agopian J, Akin C, Álvarez-Twose I, Bonadonna P, Bowman AS, Brockow K, Bumbea H, de Haro C, Fok JS, Hartmann K, Hegmann N, Hermine O, Kalisiak M, Katelaris CH, Kurz J, Marcis P, Mayne D, Mendoza D, Moussy A, Mudretzkyj G, Vaia NN, Niedoszytko M, Elberink HO, Orfao A, Radia DH, Rosenmeier S, Ribada E, Schinhofen W, Schwaab J, Siebenhaar F, Triggiani M, Tripodo G, Velazquez R, Wielink Y, Wimazal F, Yigit T, Zubrinich C, Valent P. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2039-2051. doi: 10.1016/j.jaip.2022.06.018. Epub 2022 Jun 28. PMID: 35777651.
  25. Reiter A, Gotlib J, Álvarez-Twose I, Radia DH, Lübke J, Bobbili PJ, Wang A, Norregaard C, Dimitrijevic S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky IA, Perkins C, Sperr WR, Sriskandarajah P, Chin A, Sendhil SR, Duh MS, Valent P, DeAngelo DJ. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia. 2022 Aug;36(8):2108-2120. doi: 10.1038/s41375-022-01615-z. Epub 2022 Jul 5. PMID: 35790816; PMCID: PMC9343245.
  26. Boehm T, Ristl R, Mühlbacher J, Valent P, Wahrmann M, Jilma B. Massive release of TH2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis. J Allergy Clin Immunol. 2022 Aug;150(2):406-414.e16. doi: 10.1016/j.jaci.2022.04.023. Epub 2022 Apr 30. PMID: 35504498.
  27. Valent P, Arock M, Akin C, Metcalfe DD. Recent Developments in the Field of Mast Cell Disorders: Classification, Prognostication, and Management. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2052-2055. doi: 10.1016/j.jaip.2022.04.041. PMID: 35961732.
  28. Schneeweiss-Gleixner M, Filik Y, Stefanzl G, Berger D, Sadovnik I, Bauer K, Smiljkovic D, Eisenwort G, Witzeneder N, Greiner G, Hoermann G, Schiefer AI, Schwaab J, Jawhar M, Reiter A, Sperr WR, Arock M, Valent P, Gleixner KV. CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. Cancers (Basel). 2022 Jun 23;14(13):3070. doi: 10.3390/cancers14133070. PMID: 35804842; PMCID: PMC9264943.
  29. Geissler K, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Nösslinger T, Pfeilstöcker M, Machherndl-Spandl S, Stauder R, Zebisch A, Sill H, Öhler L, Kusec R, Hoermann G, Valent P. Multistep pathogenesis of chronic myelomonocytic leukemia in patients. Eur J Haematol. 2022 Jul;109(1):50-57. doi: 10.1111/ejh.13768. Epub 2022 Mar 23. PMID: 35299281; PMCID: PMC9310570.
  30. Zeilinger EL, Lubowitzki S, Unseld M, Schneckenreiter C, Heindl D, Staber PB, Raderer M, Valent P, Zöchbauer-Müller S, Bartsch R, Prager G, Jaeger U, Gaiger A. The impact of COVID-19 on cancer care of outpatients with low socioeconomic status. Int J Cancer. 2022 Jul 1;151(1):77-82. doi: 10.1002/ijc.33960. Epub 2022 Feb 17. PMID: 35128650; PMCID: PMC9087749.
  31. Valent P, Akin C, Hartmann K, Reiter A, Gotlib J, Sotlar K, Sperr WR, Degenfeld-Schonburg L, Smiljkovic D, Triggiani M, Horny HP, Arock M, Galli SJ, Metcalfe DD. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders? J Allergy Clin Immunol. 2022 Jun;149(6):1866-1874. doi: 10.1016/j.jaci.2022.04.003. Epub 2022 Apr 12. PMID: 35421448.
  32. Arock M, Hoermann G, Sotlar K, Hermine O, Sperr WR, Hartmann K, Brockow K, Akin C, Triggiani M, Broesby-Olsen S, Reiter A, Gotlib J, Horny HP, Orfao A, Metcalfe DD, Valent P. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. J Allergy Clin Immunol. 2022 Jun;149(6):1855-1865. doi: 10.1016/j.jaci.2022.04.004. Epub 2022 Apr 14. PMID: 35430191.
  33. Tsai M, Valent P, Galli SJ. KIT as a master regulator of the mast cell lineage. J Allergy Clin Immunol. 2022 Jun;149(6):1845-1854. doi: 10.1016/j.jaci.2022.04.012. Epub 2022 Apr 22. PMID: 35469840; PMCID: PMC9177781.
  34. Akin C, Arock M, Valent P. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet? J Allergy Clin Immunol. 2022 Jun;149(6):1912-1918. doi: 10.1016/j.jaci.2022.04.020. Epub 2022 Apr 26. PMID: 35487307.
  35. Lübke J, Schwaab J, Naumann N, Horny HP, Weiß C, Metzgeroth G, Kreil S, Cross NCP, Sotlar K, Fabarius A, Hofmann WK, Valent P, Gotlib J, Jawhar M, Reiter A. Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. J Clin Oncol. 2022 Jun 1;40(16):1783-1794. doi: 10.1200/JCO.21.01849. Epub 2022 Mar 2. PMID: 35235417.
  36. Zeilinger EL, Nader IW, Wiedermann W, Gutierrez-Colosia MR, Unseld M, Lubowitzki S, Raderer M, Staber PB, Valent P, Gaiger A. Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatients. Int J Clin Health Psychol. 2022 Sep-Dec;22(3):100315. doi: 10.1016/j.ijchp.2022.100315. Epub 2022 May 26. PMID: 35662789; PMCID: PMC9157192.
  37. Valent P, Hartmann K, Bonadonna P, Niedoszytko M, Triggiani M, Arock M, Brockow K. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022. Int Arch Allergy Immunol. 2022;183(7):693-705. doi: 10.1159/000524532. Epub 2022 May 23. PMID: 35605594; PMCID: PMC9393812.
  38. Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, Valent P, Mustjoki SM, Herling M, Moriggl R, Gunning PT. JAK-STAT core cancer pathway: An integrative cancer interactome analysis. J Cell Mol Med. 2022 Apr;26(7):2049-2062. doi: 10.1111/jcmm.17228. Epub 2022 Mar 1. PMID: 35229974; PMCID: PMC8980946.
  39. Hutter K, Lindner SE, Kurschat C, Rülicke T, Villunger A, Herzog S. The miR-26 family regulates early B cell development and transformation. Life Sci Alliance. 2022 Apr 22;5(8):e202101303. doi: 10.26508/lsa.202101303. PMID: 35459737; PMCID: PMC9034462.
  40. Milosevic Feenstra JD, Jäger R, Schischlik F, Ivanov D, Eisenwort G, Rumi E, Schuster M, Gisslinger B, Machherndl-Spandl S, Bettelheim P, Krauth MT, Keil F, Bock C, Cazzola M, Gisslinger H, Kralovics R, Valent P. PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. Am J Hematol. 2022 Apr;97(4):390-400. doi: 10.1002/ajh.26461. Epub 2022 Jan 21. PMID: 35015307; PMCID: PMC9306481.
  41. Gülen T, Akin C, Metcalfe DD, Valent P. Reply to “Need to define a subgroup of patients with idiopathic mast cell activation syndrome”. J Allergy Clin Immunol Pract. 2022 Apr;10(4):1128. doi: 10.1016/j.jaip.2022.01.044. PMID: 35397815.
  42. Erdogan F, Qadree AK, Radu TB, Orlova A, de Araujo ED, Israelian J, Valent P, Mustjoki SM, Herling M, Moriggl R, Gunning PT. Structural and mutational analysis of member-specific STAT functions. Biochim Biophys Acta Gen Subj. 2022 Mar;1866(3):130058. doi: 10.1016/j.bbagen.2021.130058. Epub 2021 Nov 11. PMID: 34774983.
  43. Elst J, De Puysseleyr LP, Ebo DG, Faber MA, Van Gasse AL, van der Poorten MM, Decuyper II, Bridts CH, Mertens C, Van Houdt M, Hagendorens MM, De Clerck LS, Verlinden A, Vermeulen K, Maes MB, Berneman ZN, Valent P, Sabato V. Overexpression of FcεRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom Anaphylaxis. Front Immunol. 2022 Feb 25;13:835618. doi: 10.3389/fimmu.2022.835618. PMID: 35281031; PMCID: PMC8914951.
  44. Westers TM, Saft L, van der Velden VHJ, Te Marvelde JG, Dunlop A, Ireland R, Valent P, Porwit A, Béné MC, van de Loosdrecht AA. A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of myelodysplastic syndromes. Cytometry B Clin Cytom. 2022 Feb 18. doi: 10.1002/cyto.b.22061. Epub ahead of print. PMID: 35179296.
  45. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O’Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022 Jan 31;43(4):280-299. doi: 10.1093/eurheartj/ehab674. PMID: 34904661; PMCID: PMC8803367.
  46. Filik Y, Bauer K, Hadzijusufovic E, Haider P, Greiner G, Witzeneder N, Hoermann G, Hohensinner PJ, Gleixner KV, Wojta J, Sperr WR, Valent P. PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia. Am J Cancer Res. 2021 Dec 15;11(12):6042-6059. PMID: 35018241; PMCID: PMC8727792.
  47. Pemovska T, Bigenzahn JW, Srndic I, Lercher A, Bergthaler A, César-Razquin A, Kartnig F, Kornauth C, Valent P, Staber PB, Superti-Furga G. Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Nat Commun. 2021 Dec 14;12(1):7190. doi: 10.1038/s41467-021-27329-x. PMID: 34907165; PMCID: PMC8671470.
  48. van de Loosdrecht AA, Kern W, Porwit A, Valent P, Kordasti S, Cremers E, Alhan C, Duetz C, Dunlop A, Hobo W, Preijers F, Wagner-Ballon O, Chapuis N, Fontenay M, Bettelheim P, Eidenschink-Brodersen L, Font P, Johansson U, Loken MR, Te Marvelde JG, Matarraz S, Ogata K, Oelschlaegel U, Orfao A, Psarra K, Subirá D, Wells DA, Béné MC, Della Porta MG, Burbury K, Bellos F, van der Velden VHJ, Westers TM, Saft L, Ireland R. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group. Cytometry B Clin Cytom. 2021 Dec 13. doi: 10.1002/cyto.b.22044. Epub ahead of print. PMID: 34897979.
  49. van der Velden VHJ, Preijers F, Johansson U, Westers TM, Dunlop A, Porwit A, Béné MC, Valent P, Te Marvelde J, Wagner-Ballon O, Oelschlaegel U, Saft L, Kordasti S, Ireland R, Cremers E, Alhan C, Duetz C, Hobo W, Chapuis N, Fontenay M, Bettelheim P, Eidenshink-Brodersen L, Font P, Loken MR, Matarraz S, Ogata K, Orfao A, Psarra K, Subirá D, Wells DA, Della Porta MG, Burbury K, Bellos F, Weiß E, Kern W, van de Loosdrecht A. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet. Cytometry B Clin Cytom. 2021 Dec 11. doi: 10.1002/cyto.b.22046. Epub ahead of print. PMID: 34894176.
  50. Willmann M, Yuzbasiyan-Gurkan V, Marconato L, Dacasto M, Hadzijusufovic E, Hermine O, Sadovnik I, Gamperl S, Schneeweiss-Gleixner M, Gleixner KV, Böhm T, Peter B, Eisenwort G, Moriggl R, Li Z, Jawhar M, Sotlar K, Jensen-Jarolim E, Sexl V, Horny HP, Galli SJ, Arock M, Vail DM, Kiupel M, Valent P. Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. Front Vet Sci. 2021 Dec 10;8:755258. doi: 10.3389/fvets.2021.755258. PMID: 34957277; PMCID: PMC8702826.
  51. Kollmann S, Grausenburger R, Klampfl T, Prchal-Murphy M, Bastl K, Pisa H, Knab VM, Brandstoetter T, Doma E, Sperr WR, Lagger S, Farlik M, Moriggl RH, Valent P, Halbritter F, Kollmann K, Heller G, Maurer B, Sexl V. A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. Blood. 2021 Jul 28:blood.2021010980. doi: 10.1182/blood.2021010980. Epub ahead of print. PMID: 34320169.
  52. Bregante J, Schönbichler A, Pölöske D, Degenfeld-Schonburg L, Monzó Contreras G, Hadzijusufovic E, de Araujo ED, Valent P, Moriggl R, Orlova A. Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. Cancers (Basel). 2021 Dec 8;13(24):6181. doi: 10.3390/cancers13246181. PMID: 34944800; PMCID: PMC8699584.
  53. Boehm T, Ristl R, Joseph S, Petroczi K, Klavins K, Valent P, Jilma B. Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosis. J Allergy Clin Immunol. 2021 Dec;148(6):1533-1544. doi: 10.1016/j.jaci.2021.03.043. Epub 2021 Apr 20. PMID: 33864889.
  54. Berger D, Bauer K, Kornauth C, Gamperl S, Stefanzl G, Smiljkovic D, Sillaber C, Bettelheim P, Knöbl P, Schiefer AI, Greiner G, Thalhammer R, Hoermann G, Schwarzinger I, Staber PB, Sperr WR, Valent P. Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia. 2021 Dec;23(12):1183-1191. doi: 10.1016/j.neo.2021.09.010. Epub 2021 Oct 31. PMID: 34731787; PMCID: PMC8572856.
  55. Gülen T, Akin C, Bonadonna P, Siebenhaar F, Broesby-Olsen S, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink HNG, Butterfield JH, Sperr WR, Alvarez-Twose I, Horny HP, Sotlar K, Schwaab J, Jawhar M, Zanotti R, Nilsson G, Lyons JJ, Carter MC, George TI, Hermine O, Gotlib J, Orfao A, Triggiani M, Reiter A, Hartmann K, Castells M, Arock M, Schwartz LB, Metcalfe DD, Valent P. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3918-3928. doi: 10.1016/j.jaip.2021.06.011. Epub 2021 Jun 22. PMID: 34166845.
  56. Wardle CLW, Oldhoff JM, Diepstra A, Valent P, Horny HP, Oude Elberink HNG, Kluin PM, Diercks GFH. Case report of a clinically indolent but morphologically high-grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma? J Cutan Pathol. 2021 Nov;48(11):1404-1409. doi: 10.1111/cup.14088. Epub 2021 Jul 2. PMID: 34152029; PMCID: PMC8638666.
  57. van der Kouwe E, Heller G, Czibere A, Pulikkan JA, Agreiter C, Castilla LH, Delwel R, Di Ruscio A, Ebralidze AK, Forte M, Grebien F, Heyes E, Kazianka L, Klinger J, Kornauth C, Le T, Lind K, Barbosa IAM, Pemovska T, Pichler A, Schmolke AS, Schweicker CM, Sill H, Sperr WR, Spittler A, Surapally S, Trinh BQ, Valent P, Vanura K, Welner RS, Zuber J, Tenen DG, Staber PB. Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. Blood. 2021 Oct 14;138(15):1345-1358. doi: 10.1182/blood.2020008971. PMID: 34010414; PMCID: PMC8525333.
  58. Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, Staber PB. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders. Cancer Discov. 2021 Oct 11:candisc.0538.2021. doi: 10.1158/2159-8290.CD-21-0538. Epub ahead of print. PMID: 34635570.
  59. Maifrede S, Le BV, Nieborowska-Skorska M, Golovine K, Sullivan-Reed K, Dunuwille WMB, Nacson J, Hulse M, Keith K, Madzo J, Caruso LB, Gazze Z, Lian Z, Padella A, Chitrala KN, Bartholdy BA, Matlawska-Wasowska K, Di Marcantonio D, Simonetti G, Greiner G, Sykes SM, Valent P, Paietta EM, Tallman MS, Fernandez HF, Litzow MR, Minden MD, Huang J, Martinelli G, Vassiliou GS, Tempera I, Piwocka K, Johnson N, Challen GA, Skorski T. TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Cancer Res. 2021 Oct 1;81(19):5089-5101. doi: 10.1158/0008-5472.CAN-20-3761. Epub 2021 Jul 2. PMID: 34215619; PMCID: PMC8487956.
  60. Zanotti R, Bonifacio M, Lucchini G, Sperr WR, Scaffidi L, van Anrooij B, Oude Elberink HN, Rossignol J, Hermine O, Gorska A, Lange M, Hadzijusufovic E, Miething C, Müller S, Perkins C, Shomali W, Elena C, Illerhaus A, Jawhar M, Parente R, Caroppo F, Solomianyi O, Zink A, Mattsson M, Yavuz AS, Panse J, Varkonyi J, Doubek M, Sabato V, Breynaert C, Vucinic V, Schug T, Hägglund H, Wortmann F, Brockow K, Angelova-Fischer I, Belloni Fortina A, Triggiani M, Reiter A, Hartmann K, Malcovati L, Gotlib J, Shoumariyeh K, Niedoszytko M, Arock M, Kluin-Nelemans HC, Bonadonna P, Valent P. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia. 2021 Sep 20. doi: 10.1038/s41375-021-01406-y. Epub ahead of print. PMID: 34545185.
  61. Gleixner KV, Filik Y, Berger D, Schewzik C, Stefanzl G, Sadovnik I, Degenfeld-Schonburg L, Eisenwort G, Schneeweiss-Gleixner M, Byrgazov K, Sperr WR, Mayer J, Lion T, Valent P. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations. Am J Cancer Res. 2021 Sep 15;11(9):4470-4484. PMID: 34659899; PMCID: PMC8493398.
  62. Machherndl-Spandl S, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Geissler C, Hoermann G, Nösslinger T, Pfeilstöcker M, Bettelheim P, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Kusec R, Ulsperger E, Schneeweiss B, Öhler L, Germing U, Valent P, Tüchler H, Geissler K. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. Eur J Haematol. 2021 Aug;107(2):265-274. doi: 10.1111/ejh.13647. Epub 2021 Jun 1. PMID: 33998054; PMCID: PMC8480146.
  63. Elst J, Ebo DG, Faber MA, Van Gasse AL, Decuyper II, van der Poorten MM, Bridts CH, De Puysseleyr LP, Mertens C, Hagendorens MM, De Clerck LS, Walschot M, Verlinden A, Berger D, Valent P, Sabato V. Culturing cells with mast cell phenotype and function: Comparison of peripheral blood and bone marrow as a source. J Immunol Methods. 2021 Aug;495:113061. doi: 10.1016/j.jim.2021.113061. Epub 2021 Apr 30. PMID: 33933470.
  64. Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, Niedoszytko M, Schwaab J, Lyons JJ, Carter MC, Elberink HO, Butterfield JH, George TI, Greiner G, Ustun C, Bonadonna P, Sotlar K, Nilsson G, Jawhar M, Siebenhaar F, Broesby-Olsen S, Yavuz S, Zanotti R, Lange M, Nedoszytko B, Hoermann G, Castells M, Radia DH, Muñoz-Gonzalez JI, Sperr WR, Triggiani M, Kluin-Nelemans HC, Galli SJ, Schwartz LB, Reiter A, Orfao A, Gotlib J, Arock M, Horny HP, Metcalfe DD. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. Hemasphere. 2021 Oct 13;5(11):e646. doi: 10.1097/HS9.0000000000000646. PMID: 34901755; PMCID: PMC8659997.
  65. Naumann N, Lübke J, Shomali W, Reiter L, Horny HP, Jawhar M, Dangelo V, Fabarius A, Metzgeroth G, Kreil S, Sotlar K, Oni C, Harrison C, Hofmann WK, Cross NCP, Valent P, Radia D, Gotlib J, Reiter A, Schwaab J. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. Br J Haematol. 2021 Jul;194(2):344-354. doi: 10.1111/bjh.17567. Epub 2021 Jun 1. PMID: 34060083.
  66. Valent P, Degenfeld-Schonburg L, Sadovnik I, Horny HP, Arock M, Simon HU, Reiter A, Bochner BS. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity. Semin Immunopathol. 2021 Jun;43(3):423-438. doi: 10.1007/s00281-021-00863-y. Epub 2021 May 30. PMID: 34052871; PMCID: PMC8164832.
  67. Han SY, Mrózek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Møller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gotlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, Litzow MR, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021 May 25;5(10):2481-2489. doi: 10.1182/bloodadvances.2020003605. PMID: 34003250.
  68. Carr RM, Vorobyev D, Lasho T, Marks DL, Tolosa EJ, Vedder A, Almada LL, Yurcheko A, Padioleau I, Alver B, Coltro G, Binder M, Safgren SL, Horn I, You X, Solary E, Balasis ME, Berger K, Hiebert J, Witzig T, Buradkar A, Graf T, Valent P, Mangaonkar AA, Robertson KD, Howard MT, Kaufmann SH, Pin C, Fernandez-Zapico ME, Geissler K, Droin N, Padron E, Zhang J, Nikolaev S, Patnaik MM. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021 May 18;12(1):2901. doi: 10.1038/s41467-021-23186-w. PMID: 34006870.
  69. Niedoszytko M, Valent P, Nedoszytko B. Mastocytosis, MCAS, and Related Disorders-Diagnosis, Classification, and Therapy. Int J Mol Sci. 2021 May 10;22(9):5024. doi: 10.3390/ijms22095024. PMID: 34068468; PMCID: PMC8125991.
  70. Toledo MAS, Gatz M, Sontag S, Gleixner KV, Eisenwort G, Feldberg K, Hamouda AEI, Kluge F, Guareschi R, Rossetti G, Sechi AS, Dufva OMJ, Mustjoki SM, Maurer A, Schüler HM, Goetzke R, Braunschweig T, Kaiser A, Panse J, Jawhar M, Reiter A, Hilberg F, Ettmayer P, Wagner W, Koschmieder S, Brümmendorf TH, Valent P, Chatain N, Zenke M. Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. Blood. 2021 Apr 15;137(15):2070-2084. doi: 10.1182/blood.2019004509. Epub 2021/01/30. PMID: 33512435.
  71. Grunt TW, Lemberger L, Colomer R, López Rodríguez ML, Wagner R. The Pharmacological or Genetic Blockade of Endogenous De Novo Fatty Acid Synthesis Does Not Increase the Uptake of Exogenous Lipids in Ovarian Cancer Cells. Front Oncol. 2021 Apr 13;11:610885. doi: 10.3389/fonc.2021.610885. PMID: 33928023; PMCID: PMC8076863.
  72. Bonadonna P, Brockow K, Niedoszytko M, Elberink HO, Akin C, Nedoszytko B, Butterfield JH, Alvarez-Twose I, Sotlar K, Schwaab J, Jawhar M, Castells M, Sperr WR, Hermine O, Gotlib J, Zanotti R, Reiter A, Broesby-Olsen S, Bindslev-Jensen C, Schwartz LB, Horny HP, Radia D, Triggiani M, Sabato V, Carter MC, Siebenhaar F, Orfao A, Grattan C, Metcalfe DD, Arock M, Gulen T, Hartmann K, Valent P. COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). J Allergy Clin Immunol Pract. 2021 Apr 5. doi: 10.1016/j.jaip.2021.03.041. Epub 2021/04/09. PMID: 33831618; PMCID: PMCPMC8019658.
  73. Schneeweiss-Gleixner M, Greiner G, Herndlhofer S, Schellnegger J, Krauth MT, Gleixner KV, Wimazal F, Steinhauser C, Kundi M, Thalhammer R, Schwarzinger I, Hoermann G, Esterbauer H, Födinger M, Valent P, Sperr WR. Impact of HFE gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. Am J Cancer Res. 2021;11(3):955-967. Epub 2021/04/02. PMID: 33791166; PMCID: PMCPMC7994158.
  74. Fuchs D, Kilbertus A, Kofler K, von Bubnoff N, Shoumariyeh K, Zanotti R, Bonadonna P, Scaffidi L, Doubek M, Elberink HO, Span LFR, Hermine O, Elena C, Benvenuti P, Yavuz AS, Brockow K, Zink A, Aberer E, Gorska A, Romantowski J, Hadzijusufovic E, Fortina AB, Caroppo F, Perkins C, Illerhaus A, Panse J, Vucinic V, Jawhar M, Sabato V, Triggiani M, Parente R, Bergström A, Breynaert C, Gotlib J, Reiter A, Hartmann K, Niedoszytko M, Arock M, Kluin-Nelemans HC, Sperr WR, Greul R, Valent P. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1705-1712.e4. doi: 10.1016/j.jaip.2020.12.022. Epub 2020/12/22. PMID: 33346151.
  75. Gotlib J, Kluin-Nelemans HC, Akin C, Hartmann K, Valent P, Reiter A. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opin Biol Ther. 2021 Apr;21(4):487-498. doi: 10.1080/14712598.2021.1837109. Epub 2020/10/17. PMID: 33063554.
  76. Eisenwort G, Sadovnik I, Keller A, Ivanov D, Peter B, Berger D, Stefanzl G, Bauer K, Slavnitsch K, Greiner G, Gleixner KV, Sperr WR, Willmann M, Sill H, Bettelheim P, Geissler K, Deininger M, Rülicke T, Valent P. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia. 2021 Mar 30. doi: 10.1038/s41375-021-01227-z. Epub 2021/04/01. PMID: 33785864.
  77. Obrová K, Grumaz S, Remely M, Czurda S, Krickl I, Herndlhofer S, Gleixner KV, Sperr WR, Größlinger L, Frank T, Andrade N, Egger-Matiqi T, Peters C, Engstler G, Dworzak M, Attarbaschi A, van Grotel M, van den Heuvel-Eibrink MM, Moiseev IS, Rogacheva Y, Zubarovskaya L, Zubarovskaya N, Pichler H, Lawitschka A, Koller E, Keil F, Valent P, Sohn K, Lion T. Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. Am J Hematol. 2021 Mar 30. doi: 10.1002/ajh.26177. Epub 2021/03/31. PMID: 33784434.
  78. Panagiota V, Meggendorfer M, Kubasch AS, Gabdoulline R, Krönke J, Mies A, Shahswar R, Kandziora C, Klement P, Schiller J, Göhring G, Haferlach C, Ganster C, Shirneshan K, Gutermuth A, Thiede C, Germing U, Schroeder T, Kobbe G, Klesse S, Koenecke C, Schlegelberger B, Kröger N, Haase D, Döhner K, Sperr WR, Valent P, Ganser A, Thol F, Haferlach T, Platzbecker U, Heuser M. Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. Am J Hematol. 2021 Mar 16. doi: 10.1002/ajh.26162. Epub 2021/03/17. PMID: 33725366.
  79. Reszka E, Jabłońska E, Wieczorek E, Valent P, Arock M, Nilsson G, Nedoszytko B, Niedoszytko M. Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis. Int J Mol Sci. 2021 Mar 15;22(6). doi: 10.3390/ijms22062964. Epub 2021/04/04. PMID: 33803981; PMCID: PMCPMC7999363.
  80. Gotlib J, George T, Carter MC, Austen KF, Bochner B, Dwyer D, Lyons J, Hamilton MJ, Butterfield J, Bonadonna P, Weiler C, Galli SJ, Schwartz LB, Elberink HO, Maitland A, Theoharides T, Ustun C, Horny HP, Orfao A, Deininger M, Radia D, Jawhar M, Kluin-Nelemans H, Metcalfe DD, Arock M, Sperr WR, Valent P, Castells M, Akin C. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. J Allergy Clin Immunol. 2021 Mar 11. doi: 10.1016/j.jaci.2021.03.008. Epub 2021/03/23. PMID: 33745886.
  81. Brockow K, Plata-Nazar K, Lange M, Nedoszytko B, Niedoszytko M, Valent P. Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis. Int J Mol Sci. 2021 Mar 7;22(5). doi: 10.3390/ijms22052684. Epub 2021/04/04. PMID: 33799959; PMCID: PMCPMC7962052.
  82. Lange M, Hartmann K, Carter MC, Siebenhaar F, Alvarez-Twose I, Torrado I, Brockow K, Renke J, Irga-Jaworska N, Plata-Nazar K, Ługowska-Umer H, Czarny J, Belloni Fortina A, Caroppo F, Nowicki RJ, Nedoszytko B, Niedoszytko M, Valent P. Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. Int J Mol Sci. 2021 Mar 4;22(5). doi: 10.3390/ijms22052586. Epub 2021/04/04. PMID: 33806685; PMCID: PMCPMC7961542.
  83. Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2021 Mar;35(3):835-849. doi: 10.1038/s41375-020-0917-7. Epub 2020/07/01. PMID: 32595214; PMCID: PMCPMC7932916.
  84. Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T, Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G, Jäger U. Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. Hemasphere. 2021 Mar;5(3):e536. doi: 10.1097/hs9.0000000000000536. Epub 2021/02/25. PMID: 33623882; PMCID: PMCPMC7892291.
  85. Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, Sperr WR, Shoumariyeh K, Schwaab J, Greiner G, Henriques A, Caldas C, Fernández-Giménez C, Sánchez-Muñoz L, Mayado A, Pérez-Pons A, Schmitt-Graeff A, Duyster J, Tanasi I, Olivieri F, Mora-Casterá E, Luna I, Senent L, Bañas MH, Nuñez-García A, Jurado-Chacón M, Martín-Sánchez G, Colado E, Xicoy B, Gener-Ricós G, Gotlib J, Bonadonna P, Reiter A, Valent P, García-Montero AC, Orfao A. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematol. 2021 Mar;8(3):e194-e204. doi: 10.1016/s2352-3026(20)30400-2. Epub 2021/01/29. PMID: 33508247.
  86. Sprinzl B, Greiner G, Uyanik G, Arock M, Haferlach T, Sperr WR, Valent P, Hoermann G. Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. Int J Mol Sci. 2021 Feb 28;22(5). doi: 10.3390/ijms22052458. Epub 2021/03/07. PMID: 33671092; PMCID: PMCPMC7957558.
  87. Giannetti MP, Weller E, Alvarez-Twose I, Torrado I, Bonadonna P, Zanotti R, Dwyer DF, Foer D, Akin C, Hartmann K, Rama TA, Sperr WR, Valent P, Teodosio C, Orfao A, Castells M. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. J Allergy Clin Immunol Pract. 2021 Feb 23. doi: 10.1016/j.jaip.2021.02.023. Epub 2021/02/26. PMID: 33631409; PMCID: PMCPMC7899934.
  88. Renz H, Bachert C, Berek C, Hamelmann E, Levi-Schaffer F, Raap U, Simon HU, Ploetz S, Taube C, Valent P, Voehringer D, Werfel T, Zhang N, Ring J. Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI. Scand J Immunol. 2021 Feb 23:e13032. doi: 10.1111/sji.13032. Epub 2021/02/25. PMID: 33624312.
  89. Bauer K, Berghoff AS, Preusser M, Heller G, Zielinski CC, Valent P, Grunt TW. Degradation of BRD4 – a promising treatment approach not only for hematologic but also for solid cancer. Am J Cancer Res. 2021;11(2):530-545. Epub 2021/02/13. PMID: 33575085; PMCID: PMCPMC7868748.
  90. Aberer E, Sperr WR, Bretterklieber A, Avian A, Hadzijusufovic E, Kluin-Nelemans HC, Oude Elberink H, van Anrooij B, Niedoszytko M, Lange M, Górska A, Elena C, Brazzelli V, Belloni Fortina A, Caroppo F, Hartmann K, Illerhaus A, Reiter A, Jawhar M, Bonadonna P, Zanotti R, Triggiani M, Parente R, Gotlib J, Doubek M, von Bubnoff N, Fuchs D, Sabato V, Brockow K, Jäkel N, Panse J, Valent P. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. J Invest Dermatol. 2021 Feb 11. doi: 10.1016/j.jid.2020.12.030. Epub 2021/02/14. PMID: 33581142.
  91. Romantowski J, Górska A, Niedoszytko M, Gulen T, Gruchała-Niedoszytko M, Nedoszytko B, Lange M, Brockow K, Arock M, Akin C, Valent P. A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders. Int J Mol Sci. 2021 Feb 1;22(3). doi: 10.3390/ijms22031454. Epub 2021/02/05. PMID: 33535634; PMCID: PMCPMC7867197.
  92. Ustun C, Morgan EA, Ritz EM, Vestergaard H, Pullarkat S, Kluin PM, Ohgami R, Baughn LB, Kim Y, Ku NK, Czuchlewski D, Boe Møller M, Schiefer AI, Mrózek K, Horny HP, George TI, Kielsgaard Kristensen T, Beck T, Nathan S, Arana Yi C, Yeung C, Pullarkat V, Gotlib J, Akin C, Kohlschmidt J, Salhotra A, Soma L, Chen D, Han SY, Cho C, Sperr W, Broesby-Olsen S, Linden MA, Dolan M, Hoermann G, Hornick JL, Bloomfield C, Nakamura R, Joachim Deeg H, Litzow MR, Borthakur G, Weisdorf D, Huls G, Perales MA, Valent P, Marcucci G. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021 Feb;43(1):e19-e25. doi: 10.1111/ijlh.13338. Epub 2020/09/15. PMID: 32926565.
  93. Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021 Feb;8(2):e135-e148. doi: 10.1016/s2352-3026(20)30374-4. Epub 2021/01/30. PMID: 33513373.
  94. Jäger R, Gisslinger H, Fuchs E, Bogner E, Milosevic Feenstra JD, Weinzierl  J, Schischlik F, Gisslinger B, Schalling  M, Zörer M, Krejcy K, Klade C, Kralovics R. Germline Genetic Factors Influence Outcome of Interferon Alpha Therapy in Polycythemia Vera. Blood. 2021 Jan 21;137(3):387-391.
  95. Greiner G, Sprinzl B, Górska A, Ratzinger F, Gurbisz M, Witzeneder N, Schmetterer KG, Gisslinger B, Uyanik G, Hadzijusufovic E, Esterbauer H, Gleixner KV, Krauth MT, Pfeilstöcker M, Keil F, Gisslinger H, Nedoszytko B, Niedoszytko M, Sperr WR, Valent P, Hoermann G. Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood. 2021 Jan 14;137(2):238-247. doi: 10.1182/blood.2020006157. Epub 2020/08/11. PMID: 32777817; PMCID: PMCPMC7116780.
  96. Geissler K, Jäger E, Barna A, Graf T, Graf E, Öhler L, Hoermann G, Valent P. Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival. Eur J Haematol. 2021 Jan 12. doi: 10.1111/ejh.13577. Epub 2021/01/13. PMID: 33432601.
  97. Gamperl S, Stefanzl G, Willmann M, Valent P, Hadzijusufovic E. In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells. Vet Med Sci. 2021 Jan;7(1):57-68. doi: 10.1002/vms3.336. Epub 2020/09/15. PMID: 32924324; PMCID: PMCPMC7840218.
  98. Nedoszytko B, Arock M, Lyons JJ, Bachelot G, Schwartz LB, Reiter A, Jawhar M, Schwaab J, Lange M, Greiner G, Hoermann G, Niedoszytko M, Metcalfe DD, Valent P. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. Int J Mol Sci. 2021 Jan 2;22(1). doi: 10.3390/ijms22010411. Epub 2021/01/07. PMID: 33401724; PMCID: PMCPMC7795405.
  99. Kluin-Nelemans HC, Jawhar M, Reiter A, van Anrooij B, Gotlib J, Hartmann K, Illerhaus A, Oude Elberink HNG, Gorska A, Niedoszytko M, Lange M, Scaffidi L, Zanotti R, Bonadonna P, Perkins C, Elena C, Malcovati L, Shoumariyeh K, von Bubnoff N, Müller S, Triggiani M, Parente R, Schwaab J, Kundi M, Fortina AB, Caroppo F, Brockow K, Zink A, Fuchs D, Angelova-Fischer I, Yavuz AS, Doubek M, Mattsson M, Hagglund H, Panse J, Simonowski A, Sabato V, Schug T, Jentzsch M, Breynaert C, Várkonyi J, Kennedy V, Hermine O, Rossignol J, Arock M, Valent P, Sperr WR. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics. 2021;11(1):292-303. doi: 10.7150/thno.51872. Epub 2021/01/05. PMID: 33391475; PMCID: PMCPMC7681091.
  100. Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M, Brockow K, Siebenhaar F, Triggiani M, Arock M, Romantowski J, Górska A, Schwartz LB, Metcalfe DD. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int J Mol Sci. 2020 Nov 27;21(23). doi: 10.3390/ijms21239030. Epub 2020/12/03. PMID: 33261124; PMCID: PMCPMC7731385.
  101. Valent P, Bauer K, Sadovnik I, Smiljkovic D, Ivanov D, Herrmann H, Filik Y, Eisenwort G, Sperr WR, Rabitsch W. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues. Stem Cells Transl Med. 2020 Nov;9(11):1331-1343. doi: 10.1002/sctm.20-0147. Epub 2020/07/14. PMID: 32657052; PMCID: PMCPMC7581453.
  102. Herrmann H, Sadovnik I, Eisenwort G, Rülicke T, Blatt K, Herndlhofer S, Willmann M, Stefanzl G, Baumgartner S, Greiner G, Schulenburg A, Mueller N, Rabitsch W, Bilban M, Hoermann G, Streubel B, Vallera DA, Sperr WR, Valent P. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML. Blood Adv. 2020 Oct 27;4(20):5118-5132. doi: 10.1182/bloodadvances.2020001742. Epub 2020/10/22. PMID: 33085758; PMCID: PMCPMC7594398
  103. Le BV, Podszywalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska-Skorska M, Golovine K, Yao JC, Nejati R, Cai KQ, Caruso LB, Swatler J, Dabrowski M, Lian Z, Valent P, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Huang J, Challen GA, Link D, Tempera I, Wasik MA, Piwocka K, Skorski T. TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell Rep. 2020 Oct 6;33(1):108221. doi: 10.1016/j.celrep.2020.108221. Epub 2020/10/08. PMID: 33027668; PMCID: PMCPMC7578922.
  104. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z. Epub 2020/08/05. PMID: 32747829.
  105. Schwaab J, Cabral do OHN, Naumann N, Jawhar M, Weiß C, Metzgeroth G, Schmid A, Lübke J, Reiter L, Fabarius A, Cross NCP, Sotlar K, Valent P, Kluin-Nelemans HC, Hofmann WK, Horny HP, Panse J, Reiter A. Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. J Allergy Clin Immunol Pract. 2020 Oct;8(9):3121-3127.e1. doi: 10.1016/j.jaip.2020.05.005. Epub 2020/05/19. PMID: 32422371.
  106. Füreder W, Sperr WR, Heibl S, Zebisch A, Pfeilstöcker M, Stefanzl G, Jäger E, Greiner G, Schwarzinger I, Kundi M, Keil F, Hoermann G, Bettelheim P, Valent P. Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network. Ann Hematol. 2020 Oct;99(10):2303-2313. doi: 10.1007/s00277-020-04214-z. Epub 2020/08/29. PMID: 32856141.
  107. Grunt TW, Slany A, Semkova M, Colomer R, López-Rodríguez ML, Wuczkowski M, Wagner R, Gerner C, Stübiger G. Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. Sci Rep. 2020 Sep 10;10(1):14877.
  108. Smiljkovic D, Kiss R, Lupinek C, Hoermann G, Greiner G, Witzeneder N, Krajnik G, Trautinger F, Vrtala S, Mittermann I, Kundi M, Jilma B, Valenta R, Sperr WR, Valent P. Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2761-2768.e16. doi: 10.1016/j.jaip.2020.04.030. Epub 2020/04/30. PMID: 32348913; PMCID: PMCPMC7116130.
  109. Valent  P, Akin  C, Hartmann K, Nilsson G, Reiter  A, Hermine  O, Sotlar  K, Sperr  WR, Escribano L, George TI, Kluin-Nelemans HC, Ustun  C, Triggiani  M, Brockow K , Gotlib J, Orfao A, Kovanen PT, Hadzijusufovic E, Sadovnik I, Horny HP, Arock M, Schwartz LB, Austen KF, Metcalfe DD, Galli SJ. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich’s visions to precision medicine concepts. Theranostics. 2020 Aug 29;10(23):10743-10768.
  110. Geissler K, Jäger E, Barna A, Gurbisz M, Graf T, Graf E, Nösslinger T, Pfeilstöcker M, Machherndl-Spandl S, Stauder R, Zebisch A, Sill H, Öhler L, Kusec R, Hörmann G, Valent P. Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. Int J Mol Sci. 2020 Aug 22;21(17). doi: 10.3390/ijms21176057. Epub 2020/08/28. PMID: 32842710; PMCID: PMCPMC7504428.
  111. Hoermann G, Greiner G, Griesmacher A, Valent P. Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. J Pers Med. 2020 Aug 20;10(3). doi: 10.3390/jpm10030094. Epub 2020/08/23. PMID: 32825226; PMCID: PMCPMC7564336.
  112. Fagnan A, Bagger FO, Piqué-Borràs MR, Ignacimouttou C, Caulier A, Lopez CK, Robert E, Uzan B, Gelsi-Boyer V, Aid Z, Thirant C, Moll U, Tauchmann S, Kurtovic-Kozaric A, Maciejewski J, Dierks C, Spinelli O, Salmoiraghi S, Pabst T, Shimoda K, Deleuze V, Lapillonne H, Sweeney C, De Mas V, Leite B, Kadri Z, Malinge S, de Botton S, Micol JB, Kile B, Carmichael CL, Iacobucci I, Mullighan CG, Carroll M, Valent P, Bernard OA, Delabesse E, Vyas P, Birnbaum D, Anguita E, Garçon L, Soler E, Schwaller J, Mercher T. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood. 2020 Aug 6;136(6):698-714. doi: 10.1182/blood.2019003062. Epub 2020/05/01. PMID: 32350520.
  113. Valent P, Akin C, Bonadonna P, Brockow K, Niedoszytko M, Nedoszytko B, Butterfield JH, Alvarez-Twose I, Sotlar K, Schwaab J, Jawhar M, Reiter A, Castells M, Sperr WR, Kluin-Nelemans HC, Hermine O, Gotlib J, Zanotti R, Broesby-Olsen S, Horny HP, Triggiani M, Siebenhaar F, Orfao A, Metcalfe DD, Arock M, Hartmann K. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. J Allergy Clin Immunol. 2020 Aug;146(2):300-306. doi: 10.1016/j.jaci.2020.06.009. Epub 2020/06/21. PMID: 32561389; PMCID: PMCPMC7297685.
  114. Petzer AL, Sperr WR, Buxhofer-Ausch V, Sliwa T, Schmidt S, Greil R, Wölfler A, Pichler P, Dormann C, Burgstaller S, Tinchon C, Lang A, Goebel F, Uthman S, Muenchmeier N, Valent P. A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study. Wien Klin Wochenschr. 2020 Aug;132(15-16):415-422. doi: 10.1007/s00508-020-01690-1. Epub 2020/06/14. PMID: 32533444; PMCID: PMCPMC7445202.
  115. Hartmann K, Gotlib J, Akin C, Hermine O, Awan FT, Hexner E, Mauro MJ, Menssen HD, Redhu S, Knoll S, Sotlar K, George TI, Horny HP, Valent P, Reiter A, Kluin-Nelemans HC. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol. 2020 Aug;146(2):356-366.e4. doi: 10.1016/j.jaci.2020.03.044. Epub 2020/05/22. PMID: 32437738.
  116. Trizuljak J, Sperr WR, Nekvindová L, Elberink HO, Gleixner KV, Gorska A, Lange M, Hartmann K, Illerhaus A, Bonifacio M, Perkins C, Elena C, Malcovati L, Fortina AB, Shoumariyeh K, Jawhar M, Zanotti R, Bonadonna P, Caroppo F, Zink A, Triggiani M, Parente R, von Bubnoff N, Yavuz AS, Hägglund H, Mattsson M, Panse J, Jäkel N, Kilbertus A, Hermine O, Arock M, Fuchs D, Sabato V, Brockow K, Bretterklieber A, Niedoszytko M, van Anrooij B, Reiter A, Gotlib J, Kluin-Nelemans HC, Mayer J, Doubek M, Valent P. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy. 2020 Aug;75(8):1927-1938. doi: 10.1111/all.14248. Epub 2020/02/29. PMID: 32108361; PMCID: PMCPMC7115854.
  117. Landolina N, Zaffran I, Smiljkovic D, Serrano-Candelas E, Schmiedel D, Friedman S, Arock M, Hartmann K, Pikarsky E, Mandelboim O, Martin M, Valent P, Levi-Schaffer F. Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. Pharmacol Res. 2020 Aug;158:104682. doi: 10.1016/j.phrs.2020.104682. Epub 2020/02/09. PMID: 32035162.
  118. Füreder W, Valent P. Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report. Hemasphere. 2020 Aug;4(4):e455. doi: 10.1097/hs9.0000000000000455. Epub 2020/08/18. PMID: 32803134; PMCID: PMCPMC7410035.
  119. Nedoszytko B, Sobalska-Kwapis M, Strapagiel D, Lange M, Górska A, Elberink J, van Doormaal J, Słomka M, Kalinowski L, Gruchała-Niedoszytko M, Nowicki RJ, Valent P, Niedoszytko M. Results from a Genome-Wide Association Study (GWAS) in Mastocytosis Reveal New Gene Polymorphisms Associated with WHO Subgroups. Int J Mol Sci. 2020 Jul 31;21(15). doi: 10.3390/ijms21155506. Epub 2020/08/06. PMID: 32752121; PMCID: PMCPMC7432708.
  120. Greiner G, Ratzinger F, Gurbisz M, Witzeneder N, Taghizadeh H, Mustafa SGK, Mitterbauer-Hohendanner G, Esterbauer H, Mannhalter C, Sperr WR, Valent P, Hoermann G. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. Clin Chem Lab Med. 2020 Jul 28;58(8):1214-1222. doi: 10.1515/cclm-2019-1172. Epub 2020/02/23. PMID: 32084002; PMCID: PMCPMC7115836.
  121. Schmoellerl J, Barbosa IAM, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki-Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson R, Moriggl R, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F. CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood. 2020 Jul 23;136(4):387-400. doi: 10.1182/blood.2019003267. Epub 2020/04/29. PMID: 32344427; PMCID: PMCPMC7115844.
  122. Heibl S, Gisslinger B, Jäger E, Barna A, Gurbisz M, Stegemann M, Bettelheim P, Machherndl-Spandl S, Pfeilstöcker M, Nösslinger T, Uyanik G, Hoermann G, Stauder R, Thaler J, Kusec R, Valent P, Gisslinger H, Geissler K. Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. Cancers (Basel). 2020 Jul 14;12(7). doi: 10.3390/cancers12071891. Epub 2020/07/18. PMID: 32674283; PMCID: PMCPMC7409251.
  123. Hubmann R, Schnabl S, Araghi M, Schmidl C, Rendeiro AF, Hilgarth M, Demirtas D, Ali F, Staber PB, Valent P, Zielinski C, Jäger U, Shehata M. Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL. Cells. 2020 Jun 18;9(6). doi: 10.3390/cells9061484. Epub 2020/06/24. PMID: 32570839; PMCID: PMCPMC7348714.
  124. Valent P. Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management. Best Pract Res Clin Haematol. 2020 Jun;33(2):101137. doi: 10.1016/j.beha.2019.101137. Epub 2020/05/29. PMID: 32460976.
  125. Arock M, Sotlar K, Gotlib J, Sperr WR, Hartmann K, Schwartz LB, Akin C, Horny HP, Valent P. New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. Leuk Lymphoma. 2020 May;61(5):1075-1083. doi: 10.1080/10428194.2019.1703974. Epub 2019/12/27. PMID: 31876203; PMCID: PMCPMC7115828.
  126. Geissler K, Jäger E, Barna A, Gurbisz M, Graf T, Graf E, Nösslinger T, Pfeilstöcker M, Tüchler H, Sliwa T, Keil F, Geissler C, Heibl S, Thaler J, Machherndl-Spandl S, Zach O, Weltermann A, Bettelheim P, Stauder R, Zebisch A, Sill H, Schwarzinger I, Schneeweiss B, Öhler L, Ulsperger E, Kusec R, Germing U, Sperr WR, Knöbl P, Jäger U, Hörmann G, Valent P. Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients. Int J Mol Sci. 2020 Apr 24;21(8). doi: 10.3390/ijms21083025. Epub 2020/04/30. PMID: 32344757; PMCID: PMCPMC7215883.
  127. Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, Ivanov D, Pecnard E, Nivarthi H, Schur FKM, Filik Y, Kornauth C, Neubauer HA, Müllauer L, Tin G, Park J, de Araujo ED, Gunning PT, Hoermann G, Gouilleux F, Kralovics R, Moriggl R, Valent P. STAT5 is Expressed in CD34(+)/CD38(-) Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. Cancers (Basel). 2020 Apr 21;12(4). doi: 10.3390/cancers12041021. Epub 2020/04/25. PMID: 32326377; PMCID: PMCPMC7225958.
  128. Kluin-Nelemans HC, Reiter A, Illerhaus A, van Anrooij B, Hartmann K, Span LFR, Gorska A, Niedoszytko M, Lange M, Scaffidi L, Zanotti R, Bonadonna P, Perkins C, Elena C, Malcovati L, Shoumariyeh K, von Bubnoff N, Parente R, Triggiani M, Schwaab J, Jawhar M, Caroppo F, Fortina AB, Brockow K, Zink A, Fuchs D, Kilbertus A, Yavuz AS, Doubek M, Mattsson M, Hagglund H, Panse J, Sabato V, Aberer E, Niederwieser D, Breynaert C, Várkonyi J, Kennedy V, Lortholary O, Jakob T, Hermine O, Rossignol J, Arock M, Gotlib J, Valent P, Sperr WR. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia. 2020 Apr;34(4):1090-1101. doi: 10.1038/s41375-019-0632-4. Epub 2019/11/20. PMID: 31740811; PMCID: PMCPMC7115841.
  129. Riffel P, Schwaab J, Lutz C, Naumann N, Metzgeroth G, Fabarius A, Schoenberg SO, Hofmann WK, Valent P, Reiter A, Jawhar M. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. J Cancer Res Clin Oncol. 2020 Apr;146(4):945-951. doi: 10.1007/s00432-019-03119-3. Epub 2020/01/26. PMID: 31980928; PMCID: PMCPMC7085471.
  130. Ruiz MS, Sánchez MB, Bonecker S, Furtado C, Koile D, Yankilevich P, Cranco S, Custidiano MDR, Freitas J, Moiraghi B, Pérez MA, Pavlovsky C, Varela AI, Ventriglia V, Sánchez Ávalos JC, Larripa I, Zalcberg I, Mordoh J, Valent P, Bianchini M. miRNome profiling of LSC-enriched CD34(+)CD38(-)CD26(+) fraction in Ph(+) CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool. Front Pharmacol. 2020;11:612573. doi: 10.3389/fphar.2020.612573. Epub 2021/02/12. PMID: 33569005; PMCID: PMCPMC7869017.
  131. Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R. High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica. 2020;105(2):435-447. doi: 10.3324/haematol.2019.216986. Epub 2019/05/28. PMID: 31123029; PMCID: PMCPMC7012494.
  132. Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Class SV, Eisenwort G, Simonitsch-Klupp I, Esterbauer H, Mayerhofer M, Müllauer L, Sperr WR, Valent P, Hoermann G. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. Haematologica. 2020;105(2):366-374. doi: 10.3324/haematol.2019.217950. Epub 2019/04/26. PMID: 31018976; PMCID: PMCPMC7012478.
  133. Valent P, Sadovnik I, Eisenwort G, Herrmann H, Bauer K, Mueller N, Sperr WR, Wicklein D, Schumacher U. Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms. Semin Cancer Biol. 2020 Feb;60:191-201. doi: 10.1016/j.semcancer.2019.07.025. Epub 2019/08/14. PMID: 31408723; PMCID: PMCPMC7115853.
  134. Valent P. KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6. Haematologica. 2020 Jan;105(1):5-6. doi: 10.3324/haematol.2019.234864. Epub 2020/01/03. PMID: 31894094; PMCID: PMCPMC6939527.
  135. Huang HJ, Curin M, Banerjee S, Chen KW, Garmatiuk T, Resch-Marat Y, Carvalho-Queiroz C, Blatt K, Gafvelin G, Grönlund H, Valent P, Campana R, Focke-Tejkl M, Valenta R, Vrtala S. A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. Allergy. 2019 Dec;74(12):2461-2478. doi: 10.1111/all.13956. Epub 2019/06/23. PMID: 31228873; PMCID: PMCPMC7078969.
  136. Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink JNG, Gorska A, Niedoszytko M, Gleixner KV, Hadzijusufovic E, Zanotti R, Bonadonna P, Bonifacio M, Perkins C, Illerhaus A, Elena C, Merante S, Shoumariyeh K, von Bubnoff N, Parente R, Jawhar M, Belloni Fortina A, Caroppo F, Brockow K, Zink A, Fuchs D, Kilbertus AJ, Yavuz AS, Doubek M, Hägglund H, Panse J, Sabato V, Bretterklieber A, Niederwieser D, Breynaert C, Hartmann K, Triggiani M, Nedoszytko B, Reiter A, Orfao A, Hermine O, Gotlib J, Arock M, Kluin-Nelemans HC, Valent P. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019 Dec;6(12):e638-e649. doi: 10.1016/s2352-3026(19)30166-8. Epub 2019/11/05. PMID: 31676322; PMCID: PMCPMC7115823.
  137. Gamperl S, Stefanzl G, Peter B, Smiljkovic D, Bauer K, Willmann M, Valent P, Hadzijusufovic E. Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. Vet Comp Oncol. 2019 Dec;17(4):553-561. doi: 10.1111/vco.12520. Epub 2019/07/10. PMID: 31286638; PMCID: PMCPMC6900099.
  138. Schneeweiss-Gleixner M, Byrgazov K, Stefanzl G, Berger D, Eisenwort G, Lucini CB, Herndlhofer S, Preuner S, Obrova K, Pusic P, Witzeneder N, Greiner G, Hoermann G, Sperr WR, Lion T, Deininger M, Valent P, Gleixner KV. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML. EBioMedicine. 2019 Dec;50:111-121. doi: 10.1016/j.ebiom.2019.11.004. Epub 2019/11/26. PMID: 31761618; PMCID: PMCPMC6921367.
  139. Eisenwort G, Sadovnik I, Schwaab J, Jawhar M, Keller A, Stefanzl G, Berger D, Blatt K, Hoermann G, Bilban M, Willmann M, Winding C, Sperr WR, Arock M, Rülicke T, Reiter A, Valent P. Identification of a leukemia-initiating stem cell in human mast cell leukemia. Leukemia. 2019 Nov;33(11):2673-2684. doi: 10.1038/s41375-019-0460-6. Epub 2019/04/07. PMID: 30953030; PMCID: PMCPMC6839966.
  140. Jawhar M, Schwaab J, Álvarez-Twose I, Shoumariyeh K, Naumann N, Lübke J, Perkins C, Muñoz-González JI, Meggendorfer M, Kennedy V, Metzgeroth G, Fabarius A, Pfeifer D, Sotlar K, Horny HP, von Bubnoff N, Haferlach T, Cross NCP, Hofmann WK, Sperr WR, García-Montero AC, Valent P, Gotlib J, Orfao A, Reiter A. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. J Clin Oncol. 2019 Nov 1;37(31):2846-2856. doi: 10.1200/jco.19.00640. Epub 2019/09/12. PMID: 31509472; PMCID: PMCPMC6823885.
  141. Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, Liang Y, Kwiatkowski NP, Fux D, Hoelbl-Kovacic A, Kubicek S, Melo JV, Valent P, Weichhart T, Grebien F, Zuber J, Gray NS, Sexl V. A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia. Nat Commun. 2019 Oct 18;10(1):4741. doi: 10.1038/s41467-019-12656-x. Epub 2019/10/20. PMID: 31628323; PMCID: PMCPMC6802219
  142. Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019 Oct;104(10):1935-1949. doi: 10.3324/haematol.2019.222059. Epub 2019/05/03. PMID: 31048353; PMCID: PMCPMC6886439.
  143. Geissler K, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Borjan B, Jilch R, Geissler C, Hoermann G, Esterbauer H, Schwarzinger I, Nösslinger T, Pfeilstöcker M, Tüchler H, Reisner R, Sliwa T, Keil F, Bettelheim P, Machherndl-Spandl S, Doleschal B, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Petzer A, Kusec R, Ulsperger E, Schneeweiss B, Berger J, Öhler L, Germing U, Sperr WR, Knöbl P, Jäger U, Valent P. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr. 2019 Sep;131(17-18):410-418. doi: 10.1007/s00508-019-1526-1. Epub 2019/07/20. PMID: 31321531; PMCID: PMCPMC6748886.
  144. Valent P, Sadovnik I, Eisenwort G, Bauer K, Herrmann H, Gleixner KV, Schulenburg A, Rabitsch W, Sperr WR, Wolf D. Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. Int J Mol Sci. 2019 Aug 29;20(17). doi: 10.3390/ijms20174233. Epub 2019/09/01. PMID: 31470642; PMCID: PMCPMC6747233.
  145. Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. 2019 Aug;37(3):240-252. doi: 10.1002/hon.2622. Epub 2019/04/24. PMID: 31013548.
  146. Valent P, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, Triggiani M, Lyons JJ, Oude Elberink JNG, Arock M, Metcalfe DD, Akin C. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. Int Arch Allergy Immunol. 2019;180(1):44-51. doi: 10.1159/000501079. Epub 2019/07/01. PMID: 31256161; PMCID: PMCPMC7115850.
  147. Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster MK, Holly R, Fuchs E, Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D, Fischer GF, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A, Bock C, Cazzola M, Gisslinger H, Kralovics R. Mutational Landscape of the Transcriptome Offers Putative Targets for Immunotherapy of Myeloproliferative Neoplasms. Blood 2019;134(2):199-210.
  148. Schmidt L, Heyes E, Scheiblecker L, Eder T, Volpe G, Frampton J, Nerlov C, Valent P, Grembecka J, Grebien F. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. Leukemia. 2019 Jul;33(7):1608-1619. doi: 10.1038/s41375-019-0382-3. Epub 2019/01/27. PMID: 30679799; PMCID: PMCPMC6612510.
  149. Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, Huuhtanen J, Lagger S, Hennighausen L, Valent P, Decker T, Strobl B, Mueller M, Mustjoki S, Hoelbl-Kovacic A, Sexl V. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. Leukemia. 2019 Jul;33(7):1583-1597. doi: 10.1038/s41375-018-0369-5. Epub 2019/01/27. PMID: 30679796; PMCID: PMCPMC6755975
  150. Valent P, Akin C, Gleixner KV, Sperr WR, Reiter A, Arock M, Triggiani M. Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. Int J Mol Sci. 2019 Jun 18;20(12). doi: 10.3390/ijms20122976. Epub 2019/06/21. PMID: 31216696; PMCID: PMCPMC6627900.
  151. Jawhar M, Döhner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendorfer M, Span LLF, Fuhrmann S, Naumann N, Horny HP, Sotlar K, Kubuschok B, von Bubnoff N, Spiekermann K, Heuser M, Metzgeroth G, Fabarius A, Klein S, Hofmann WK, Kluin-Nelemans HC, Haferlach T, Döhner H, Cross NCP, Sperr WR, Valent P, Reiter A. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia. 2019 May;33(5):1124-1134. doi: 10.1038/s41375-018-0346-z. Epub 2019/01/13. PMID: 30635631; PMCID: PMCPMC6756067
  152. Uras IZ, Maurer B, Nivarthi H, Jodl P, Kollmann K, Prchal-Murphy M, Milosevic Feenstra JD, Zojer M, Lagger S, Grausenburger R, Grabner B, Holly R, Kavirayani A, Bock C, Gisslinger H, Valent P, Kralovics R, Sexl V. CDK6 coordinates JAK2 (V617F) mutant MPN via NF-κB and apoptotic networks. Blood. 2019 Apr 11;133(15):1677-1690. doi: 10.1182/blood-2018-08-872648. Epub 2019/01/13. PMID: 30635286; PMCID: PMCPMC6543514 interests.
  153. Russell N, Jennings S, Jennings B, Slee V, Sterling L, Castells M, Valent P, Akin C. The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and Beyond. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1157-1165.e6. doi: 10.1016/j.jaip.2018.07.032. Epub 2018/08/12. PMID: 30098409.
  154. Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T. Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leuk Lymphoma. 2019 Apr;60(4):1098-1101. doi: 10.1080/10428194.2018.1520988. Epub 2018/10/03. PMID: 30277116; PMCID: PMCPMC6445778.
  155. Valent P, Akin C. Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1109-1114. doi: 10.1016/j.jaip.2018.11.045. Epub 2019/04/10. PMID: 30961836.
  156. Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, Nedoszytko B, Siebenhaar F, Sperr WR, Oude Elberink JNG, Butterfield JH, Alvarez-Twose I, Sotlar K, Reiter A, Kluin-Nelemans HC, Hermine O, Gotlib J, Broesby-Olsen S, Orfao A, Horny HP, Triggiani M, Arock M, Schwartz LB, Metcalfe DD. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1125-1133.e1. doi: 10.1016/j.jaip.2019.01.006. Epub 2019/02/10. PMID: 30737190; PMCID: PMCPMC6643056.
  157. Najafi N, Hofer G, Gattinger P, Smiljkovic D, Blatt K, Selb R, Stoecklinger A, Keller W, Valent P, Niederberger V, Thalhamer J, Valenta R, Flicker S. Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates with reduced allergenic activity. Sci Rep. 2019 Mar 8;9(1):4006. doi: 10.1038/s41598-019-39798-8. Epub 2019/03/10. PMID: 30850635; PMCID: PMCPMC6408504
  158. Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 2019;216(3):688-703.
  159. Boehm T, Reiter B, Ristl R, Petroczi K, Sperr W, Stimpfl T, Valent P, Jilma B. Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. Allergy. 2019 Mar;74(3):583-593. doi: 10.1111/all.13663. Epub 2018/11/13. PMID: 30418682; PMCID: PMCPMC6590243.
  160. Willmann M, Hadzijusufovic E, Hermine O, Dacasto M, Marconato L, Bauer K, Peter B, Gamperl S, Eisenwort G, Jensen-Jarolim E, Müller M, Arock M, Vail DM, Valent P. Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. Vet Comp Oncol. 2019 Mar;17(1):1-10. doi: 10.1111/vco.12440. Epub 2018/08/24. PMID: 30136349; PMCID: PMCPMC6378619.
  161. Gleixner KV, Sadovnik I, Schneeweiss M, Eisenwort G, Byrgazov K, Stefanzl G, Berger D, Herrmann H, Hadzijusufovic E, Lion T, Valent P. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1(T315I) in Ph+ CML. Leuk Res. 2019 Mar;78:36-44. doi: 10.1016/j.leukres.2018.12.013. Epub 2019/02/04. PMID: 30711891; PMCID: PMCPMC6834439.
  162. Valent P, Kern W, Hoermann G, Milosevic Feenstra JD, Sotlar K, Pfeilstöcker M, Germing U, Sperr WR, Reiter A, Wolf D, Arock M, Haferlach T, Horny HP. Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. Int J Mol Sci. 2019 Feb 12;20(3). doi: 10.3390/ijms20030789. Epub 2019/02/15. PMID: 30759825; PMCID: PMCPMC6387423.
  163. Neukirchen-Strapatsas J, Tuechler H, Porta MD, Fenaux P, Guerci A, Haas R, Rossi M, Sapena R, Sperr WR, Strupp C, Stamatoullas A, Valent P, Germing U, Bennett JM. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. Leuk Res. 2019 Feb;77:8-13. doi: 10.1016/j.leukres.2018.12.012. Epub 2019/01/04. PMID: 30605856.
  164. Rogers-Broadway KR, Kumar J, Sisu C, Wander G, Mazey E, Jeyaneethi J, Pados G, Tsolakidis D, Klonos E, Grunt T, Hall M, Chatterjee J, Karteris E. Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry. Int J Mol Med. 2019;43(1):47-56.
  165. Valent P. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. Pathobiology. 2019;86(1):30-38. doi: 10.1159/000489042. Epub 2018/06/04. PMID: 29860246; PMCID: PMCPMC7115849.
  166. Valent P, Oude Elberink JNG, Gorska A, Lange M, Zanotti R, van Anrooij B, Bonifacio M, Bonadonna P, Gleixner KV, Hadzijusufovic E, Perkins C, Hartmann K, Illerhaus A, Merante S, Elena C, Shoumariyeh K, von Bubnoff N, Parente R, Triggiani M, Schwaab J, Jawhar M, Caroppo F, Fortina AB, Brockow K, David F, Greul R, Yavuz AS, Doubek M, Mattsson M, Hagglund H, Panse J, Sabato V, Aberer E, Al-Ali HK, Morren MA, Varkonyi J, Zink A, Niedoszytko M, Niederwieser D, Malcovati L, Reiter A, Kennedy V, Gotlib J, Lortholary O, Hermine O, Arock M, Kluin-Nelemans H, Sperr WR. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. J Allergy Clin Immunol Pract. 2019 Jan;7(1):81-87. doi: 10.1016/j.jaip.2018.09.024. Epub 2018/11/13. PMID: 30416055; PMCID: PMCPMC7115815.
  167. Uras IZ, Maurer B, Nebenfuehr S, Zojer M, Valent P, Sexl V. Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib. Int J Mol Sci. 2018 Dec 11;19(12). doi: 10.3390/ijms19123987. Epub 2018/12/14. PMID: 30544932; PMCID: PMCPMC6321303.
  168. Arock M, Wedeh G, Hoermann G, Bibi S, Akin C, Peter B, Gleixner KV, Hartmann K, Butterfield JH, Metcalfe DD, Valent P. Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. Haematologica. 2018 Nov;103(11):1760-1771. doi: 10.3324/haematol.2018.195867. Epub 2018/07/07. PMID: 29976735; PMCID: PMCPMC6278969.
  169. Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, Greiner G, Boehm A, Kornauth C, Muellauer L, Sehner S, Hoermann G, Sperr WR, Staber PB, Jaeger U, Zuber J, Arock M, Schumacher U, Reiter A, Valent P. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood. 2018 Nov 1;132(18):1936-1950. doi: 10.1182/blood-2018-02-833582. Epub 2018/07/19. PMID: 30018080; PMCID: PMCPMC6382065.
  170. Schanz J, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes Cancer. 2018 Nov;57(11):547-556. doi: 10.1002/gcc.22667. Epub 2018/09/25. PMID: 30248204.
  171. Merante S, Ferretti VV, Elena C, Brazzelli V, Zanotti R, Neri I, Magliacane D, Belloni Fortina A, Ingeborg F, Pastorello EA, Pieri L, Papayannidis C, Mauro M, Grifoni F, Minelli R, Guggiari E, Difonzo E, Bocchia M, Caroppo F, Di Nuzzo S, Elli EM, Rondoni M, Ciccocioppo R, Di Stefano M, Bossi G, Boveri E, Bonadonna P, Giona F, Valent P, Triggiani M. The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. Future Oncol. 2018 Nov;14(26):2713-2723. doi: 10.2217/fon-2018-0291. Epub 2018/09/13. PMID: 30207489.
  172. Valent P, Büsche G, Theurl I, Uras IZ, Germing U, Stauder R, Sotlar K, Füreder W, Bettelheim P, Pfeilstöcker M, Oberbauer R, Sperr WR, Geissler K, Schwaller J, Moriggl R, Béné MC, Jäger U, Horny HP, Hermine O. Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica. 2018 Oct;103(10):1593-1603. doi: 10.3324/haematol.2018.192518. Epub 2018/08/05. PMID: 30076180; PMCID: PMCPMC6165792.
  173. Valent P, Horny HP, Arock M. The underestimated role of basophils in Ph(+) chronic myeloid leukaemia. Eur J Clin Invest. 2018 Oct;48(10):e13000. doi: 10.1111/eci.13000. Epub 2018/07/19. PMID: 30019447; PMCID: PMCPMC6175372.
  174. Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018/09/17. PMID: 30219650.
  175. Valent P, Akin C, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, Reiter A, Gotlib J, Castells M, Milner JD, Carter MC, Komarow H, Radia D, Pardanani A, Sotlar K, Triggiani M, Horny HP, Arock M, Schwartz LB, Metcalfe DD. Mast cell activation syndrome: Importance of consensus criteria and call for research. J Allergy Clin Immunol. 2018 Sep;142(3):1008-1010. doi: 10.1016/j.jaci.2018.06.004. Epub 2018/06/22. PMID: 29928922; PMCID: PMCPMC7115848.
  176. Kaivers J, Lauseker M, Hildebrandt B, Fenaux P, Pfeilstöcker M, Valent P, Platzbecker U, Latagliata R, Oliva EN, Xicoy B, Götze K, Ganster C, Haase D, Bug G, Kündgen A, Gattermann N, Haas R, Germing U. The IPSS-R has prognostic impact in untreated patients with MDS del(5q). Leuk Res. 2018 Sep;72:27-33. doi: 10.1016/j.leukres.2018.07.019. Epub 2018/08/04. PMID: 30075323.
  177. Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M, Hubmann R, Shehata M, Selzer E, Gleixner KV, Rülicke T, Sperr WR, Marian B, Pfeilstöcker M, Pehamberger H, Keil F, Jäger U, Zielinski C. Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. Wien Klin Wochenschr. 2018 Sep;130(17-18):517-529. doi: 10.1007/s00508-018-1355-7. Epub 2018/07/15. PMID: 30006759; PMCID: PMCPMC6132878.
  178. Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrózek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Møller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G. Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). Cancer Med. 2018 Sep;7(9):4447-4455. doi: 10.1002/cam4.1733. Epub 2018/08/18. PMID: 30117318; PMCID: PMCPMC6144246.
  179. Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018/06/17. PMID: 29907599; PMCID: PMCPMC7115916.
  180. Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Müller M, Moriggl R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018 Aug;32(8):1713-1726. doi: 10.1038/s41375-018-0117-x. Epub 2018/05/08. PMID: 29728695; PMCID: PMCPMC6087715.
  181. Füreder W, Sperr WR, Gleixner K, Thalhammer R, Schwarzinger I, Hoermann G, Kornauth C, Grünberger B, Valent P. Major response of PNH to an AML chemotherapy protocol. Ann Hematol. 2018 Aug;97(8):1487-1488. doi: 10.1007/s00277-018-3307-8. Epub 2018/03/24. PMID: 29568989.
  182. Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018/05/23. PMID: 29784639; PMCID: PMCPMC6034642 interests.
  183. Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, Ghelli Luserna di Rorá A, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, Soverini S, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G. Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Leukemia. 2018; 32(7):1609-1620.
  184. Gadermaier E, Marth K, Lupinek C, Campana R, Hofer G, Blatt K, Smiljkovic D, Roder U, Focke-Tejkl M, Vrtala S, Keller W, Valent P, Valenta R, Flicker S. Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments. Allergy. 2018 Jul;73(7):1425-1435. doi: 10.1111/all.13394. Epub 2018/01/10. PMID: 29315611; PMCID: PMCPMC6032869.
  185. Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034. Epub 2018/06/14. PMID: 29898385; PMCID: PMCPMC6082171.
  186. Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P. Phenotyping and Target Expression Profiling of CD34(+)/CD38(-) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. Neoplasia. 2018 Jun;20(6):632-642. doi: 10.1016/j.neo.2018.04.004. Epub 2018/05/18. PMID: 29772458; PMCID: PMCPMC5994777.
  187. Bauer K, Berger D, Zielinski CC, Valent P, Grunt TW. Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. Oncotarget. 2018 May 29;9(41):26491-26506. doi: 10.18632/oncotarget.25474. Epub 2018/06/15. PMID: 29899872; PMCID: PMCPMC5995173.
  188. Skucha A, Ebner J, Schmöllerl J, Roth M, Eder T, César-Razquin A, Stukalov A, Vittori S, Muhar M, Lu B, Aichinger M, Jude J, Müller AC, Győrffy B, Vakoc CR, Valent P, Bennett KL, Zuber J, Superti-Furga G, Grebien F. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun. 2018 May 18;9(1):1983. doi: 10.1038/s41467-018-04329-y. Epub 2018/05/20. PMID: 29777171; PMCID: PMCPMC5959866.
  189. Valenta R, Karaulov A, Niederberger V, Gattinger P, van Hage M, Flicker S, Linhart B, Campana R, Focke-Tejkl M, Curin M, Eckl-Dorna J, Lupinek C, Resch-Marat Y, Vrtala S, Mittermann I, Garib V, Khaitov M, Valent P, Pickl WF. Molecular Aspects of Allergens and Allergy. Adv Immunol. 2018;138:195-256. doi: 10.1016/bs.ai.2018.03.002. Epub 2018/05/08. PMID: 29731005.
  190. Eckl-Dorna J, Fröschl R, Lupinek C, Kiss R, Gattinger P, Marth K, Campana R, Mittermann I, Blatt K, Valent P, Selb R, Mayer A, Gangl K, Steiner I, Gamper J, Perkmann T, Zieglmayer P, Gevaert P, Valenta R, Niederberger V. Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study. Allergy. 2018 May;73(5):1003-1012. doi: 10.1111/all.13343. Epub 2017/10/31. PMID: 29083477; PMCID: PMCPMC5969304.
  191. Burgstaller S, Stauder R, Kuehr T, Lang A, Machherndl-Spandl S, Mayrbaeurl B, Noesslinger T, Petzer A, Valent P, Greil R, Thaler J. A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1. Leuk Lymphoma. 2018 May;59(5):1121-1126. doi: 10.1080/10428194.2017.1369070. Epub 2017/08/31. PMID: 28853315.
  192. Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau CH, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018 May;32(5):1135-1146. doi: 10.1038/s41375-017-0005-9. Epub 2018/02/24. PMID: 29472718; PMCID: PMCPMC5940656.
  193. Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018/02/14. PMID: 29439183; PMCID: PMCPMC5927976.
  194. Naumann N, Jawhar M, Schwaab J, Kluger S, Lübke J, Metzgeroth G, Popp HD, Khaled N, Horny HP, Sotlar K, Valent P, Haferlach C, Göhring G, Schlegelberger B, Meggendorfer M, Hofmann WK, Cross NCP, Reiter A, Fabarius A. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. Genes Chromosomes Cancer. 2018 May;57(5):252-259. doi: 10.1002/gcc.22526. Epub 2018/01/18. PMID: 29341334.
  195. Demyanets S, Jaeger E, Pablik E, Greiner G, Herndlhofer S, Valent P, Schwarzinger I. The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia. Br J Haematol. 2018 Apr;181(1):137-139. doi: 10.1111/bjh.14508. Epub 2017/02/22. PMID: 28220937.
  196. Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017/12/19. PMID: 29249817; PMCID: PMCPMC6037300.
  197. Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S, Reifinger M, Cerny-Reiterer S, Moriggl R, Willmann M, Valent P, Hadzijusufovic E. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. Vet Comp Oncol. 2018 Mar;16(1):55-68. doi: 10.1111/vco.12311. Epub 2017/04/12. PMID: 28397975; PMCID: PMCPMC5824979.
  198. Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Simonitsch-Klupp I, Mitterbauer-Hohendanner G, Mayerhofer M, Müllauer L, Sperr WR, Valent P, Hoermann G. Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. Clin Chem. 2018 Mar;64(3):547-555. doi: 10.1373/clinchem.2017.277897. Epub 2017/12/15. PMID: 29237714; PMCID: PMCPMC7115889.
  199. Hatch EW, Geeze MB, Martin C, Salama ME, Hartmann K, Eisenwort G, Blatt K, Valent P, Gotlib J, Lee JH, Chen L, Ward HH, Lidke DS, George TI. Variability of PD-L1 expression in mastocytosis. Blood Adv. 2018 Feb 13;2(3):189-199. doi: 10.1182/bloodadvances.2017011551. Epub 2018/01/31. PMID: 29378725; PMCID: PMCPMC5812326
  200. Grunt T. Interacting Cancer Machineries: Cell Signaling, Lipid Metabolism and Epigenetics. Trends in Endocrinology and Metabolism. 2018;29(2):86-98.
  201. Valent P, Stauder R, Theurl I, Geissler K, Sliwa T, Sperr WR, Bettelheim P, Sill H, Pfeilstöcker M. Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. Expert Rev Hematol. 2018 Feb;11(2):109-116. doi: 10.1080/17474086.2018.1420473. Epub 2018/01/03. PMID: 29292655.
  202. Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications, and management. Blood. 2018 Feb 1;131(5):505-514. doi: 10.1182/blood-2017-07-746446. Epub 2017/11/17. PMID: 29141943.
  203. Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/jci94509. Epub 2017/12/05. PMID: 29200404; PMCID: PMCPMC5749501.
  204. Willmann M, Sadovnik I, Eisenwort G, Entner M, Bernthaler T, Stefanzl G, Hadzijusufovic E, Berger D, Herrmann H, Hoermann G, Valent P, Rülicke T. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph(+) chronic myeloid leukemia. Exp Hematol. 2018 Jan;57:50-59.e6. doi: 10.1016/j.exphem.2017.09.012. Epub 2017/10/17. PMID: 29031704; PMCID: PMCPMC7115814.
  205. Byrgazov K, Lucini CB, Valent P, Hantschel O, Lion T. BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. Haematologica. 2018 Jan;103(1):e10-e12. doi: 10.3324/haematol.2017.176347. Epub 2017/10/07. PMID: 28983061; PMCID: PMCPMC5777206.
  206. Martinelli G, Mancini M, De Benedittis C, Rondoni M, Papayannidis C, Manfrini M, Meggendorfer M, Calogero R, Guadagnuolo V, Fontana MC, Bavaro L, Padella A, Zago E, Pagano L, Zanotti R, Scaffidi L, Specchia G, Albano F, Merante S, Elena C, Savini P, Gangemi D, Tosi P, Ciceri F, Poletti G, Riccioni L, Morigi F, Delledonne M, Haferlach T, Cavo M, Valent P, Soverini S. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. Leukemia. 2018 Jan;32(1):139-148. doi: 10.1038/leu.2017.183. Epub 2017/07/01. PMID: 28663576; PMCID: PMCPMC5770597.
  207. Orlova A, Wingelhofer B, Neubauer HA, Maurer B, Berger-Becvar A, Keserű GM, Gunning PT, Valent P, Moriggl R. Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi: 10.1080/14728222.2018.1406924. Epub 2017/11/18. PMID: 29148847; PMCID: PMCPMC5743003.